Palvella Therapeutics, Inc. 8-K Filing
Ticker: PVLA · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0001583648
| Field | Detail |
|---|---|
| Company | Palvella Therapeutics, Inc. (PVLA) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2026 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Palvella Therapeutics, Inc. (ticker: PVLA) to the SEC on Apr 7, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common stock, $0.001 par value per share PVLA The Nasdaq).
How long is this filing?
Palvella Therapeutics, Inc.'s 8-K filing is 1 pages with approximately 439 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2026-04-07 07:30:15
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share PVLA The Nasdaq
Filing Documents
- pvla-20260407.htm (8-K) — 46KB
- pvla-ex99_1.htm (EX-99.1) — 48KB
- pvla-ex99_1s1.jpg (GRAPHIC) — 237KB
- pvla-ex99_1s2.jpg (GRAPHIC) — 812KB
- pvla-ex99_1s3.jpg (GRAPHIC) — 385KB
- pvla-ex99_1s4.jpg (GRAPHIC) — 429KB
- pvla-ex99_1s5.jpg (GRAPHIC) — 376KB
- pvla-ex99_1s6.jpg (GRAPHIC) — 430KB
- pvla-ex99_1s7.jpg (GRAPHIC) — 315KB
- pvla-ex99_1s8.jpg (GRAPHIC) — 177KB
- pvla-ex99_1s9.jpg (GRAPHIC) — 385KB
- pvla-ex99_1s10.jpg (GRAPHIC) — 348KB
- pvla-ex99_1s11.jpg (GRAPHIC) — 290KB
- pvla-ex99_1s12.jpg (GRAPHIC) — 345KB
- pvla-ex99_1s13.jpg (GRAPHIC) — 168KB
- pvla-ex99_1s14.jpg (GRAPHIC) — 404KB
- pvla-ex99_1s15.jpg (GRAPHIC) — 391KB
- pvla-ex99_1s16.jpg (GRAPHIC) — 446KB
- pvla-ex99_1s17.jpg (GRAPHIC) — 396KB
- pvla-ex99_1s18.jpg (GRAPHIC) — 391KB
- pvla-ex99_1s19.jpg (GRAPHIC) — 350KB
- pvla-ex99_1s20.jpg (GRAPHIC) — 302KB
- pvla-ex99_1s21.jpg (GRAPHIC) — 338KB
- pvla-ex99_1s22.jpg (GRAPHIC) — 366KB
- pvla-ex99_1s23.jpg (GRAPHIC) — 269KB
- pvla-ex99_1s24.jpg (GRAPHIC) — 160KB
- pvla-ex99_1s25.jpg (GRAPHIC) — 328KB
- pvla-ex99_1s26.jpg (GRAPHIC) — 367KB
- pvla-ex99_1s27.jpg (GRAPHIC) — 361KB
- pvla-ex99_1s28.jpg (GRAPHIC) — 327KB
- pvla-ex99_1s29.jpg (GRAPHIC) — 164KB
- pvla-ex99_1s30.jpg (GRAPHIC) — 393KB
- pvla-ex99_1s31.jpg (GRAPHIC) — 393KB
- pvla-ex99_1s32.jpg (GRAPHIC) — 372KB
- pvla-ex99_1s33.jpg (GRAPHIC) — 370KB
- pvla-ex99_1s34.jpg (GRAPHIC) — 292KB
- pvla-ex99_1s35.jpg (GRAPHIC) — 330KB
- pvla-ex99_1s36.jpg (GRAPHIC) — 169KB
- pvla-ex99_1s37.jpg (GRAPHIC) — 445KB
- pvla-ex99_1s38.jpg (GRAPHIC) — 174KB
- pvla-ex99_1s39.jpg (GRAPHIC) — 403KB
- pvla-ex99_1s40.jpg (GRAPHIC) — 401KB
- pvla-ex99_1s41.jpg (GRAPHIC) — 390KB
- pvla-ex99_1s42.jpg (GRAPHIC) — 310KB
- pvla-ex99_1s43.jpg (GRAPHIC) — 133KB
- pvla-ex99_1s44.jpg (GRAPHIC) — 348KB
- pvla-ex99_1s45.jpg (GRAPHIC) — 128KB
- pvla-ex99_1s46.jpg (GRAPHIC) — 354KB
- pvla-ex99_1s47.jpg (GRAPHIC) — 372KB
- pvla-ex99_1s48.jpg (GRAPHIC) — 153KB
- 0001193125-26-144540.txt ( ) — 22233KB
- pvla-20260407.xsd (EX-101.SCH) — 25KB
- pvla-20260407_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On April 7, 2026, Palvella Therapeutics, Inc. (the " Company ") posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is filed herewith as Exhibit 99.1, and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of Palvella Therapeutics, Inc., dated April 7, 2026* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PALVELLA THERAPEUTICS, INC. Date: April 7, 2026 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer